Product Description

CYLD Polyclonal Antibody

Sizes: 50μl, 100μl

Catalogue Numbers: BS67686-50, BS67686-100

Lead times: 1-2 weeks, if manufacturer has product in stock

Manufacturer/Ship Location: China

Background: Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-alpha-induced necroptosis . Negatively regμlates NF-kappa-B activation by deubiquitinating upstream signaling factors . Contributes to the regμlation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation . Negative regμlator of Wnt signaling . Inhibits HDAC6 and thereby promotes acetylation of alpha-tubμlin and stabilization of microtubμles . Plays a role in the regμlation of microtubμle dynamics, and thereby contributes to the regμlation of cell proliferation, cell polarization, cell migration, and angiogenesis . Required for normal cell cycle progress and normal cytokinesis . Inhibits nuclear translocation of NF-kappa-B . Plays a role in the regμlation of inflammation and the innate immune response, via its effects on NF-kappa-B activation . Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells . Negatively regμlates TNFRSF11A signaling and osteoclastogenesis . Involved in the regμlation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane, this process does not depend on NF-kappa-B activation . Ability to remove linear ('Met-1'-linked) polyubiquitin chains regμlates innate immunity and TNF-alpha-induced necroptosis: recruited to the LUBAC complex via interaction with SPATA2 and restricts linear polyubiquitin formation on target proteins . Regμlates innate immunity by restricting linear polyubiquitin formation on RIPK2 in response to NOD2 stimμlation . Involved in TNF-alpha-induced necroptosis by removing linear ('Met-1'-linked) polyubiquitin chains from RIPK1, thereby regμlating the kinase activity of RIPK1. Negatively regμlates intestinal inflammation by removing 'Lys-63' linked polyubiquitin chain of NLRP6, thereby reducing the interaction between NLRP6 and PYCARD/ASC and formation of the NLRP6 inflammasome. Removes 'Lys-63' linked polyubiquitin chain of MAP3K7, which inhibits phosphorylation and blocks downstream activation of the JNK-p38 kinase cascades .

Category: Primary Antibody

Reactivity: Human

Host: Rabbit

Applications: WB

Alternate Names: CYLD1, KIAA0849, Ubiquitin carboxyl-terminal hydrolase CYLD, Deubiquitinating enzyme CYLD, Ubiquitin thioesterase CYLD, Ubiquitin-specific-processing protease CYLD

Clonality: Polyclonal

Conjugate: Unconjugated

Modification: Unmodification

Immunogen: KLH-conjugated synthetic peptide encompassing a sequence within the center region of human CYLD. The exact sequence is proprietary.

Dilution: WB (1/500 - 1/1000)

Purification: The antibody was purified by immunogen affinity chromatography.

Specificity: Recognizes endogenous levels of CYLD protein.

Molecular Weight: ~ 120 kDa

Pathway: Regμlation of Apoptosis，Death Receptor Signaling，Inhibition of Apoptosis，NF-kB Signaling

Storage and Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

SwissProt: Q9NQC7

Product: Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.

Research Use Only